These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 404132)

  • 41. Enhancement of the hypertensinogenic action of 19-hydroxyandrostenedione by aromatase inhibitor, delta 1-testololactone.
    Sekihara H; Yonemitsu K; Takaku F
    Endocrinology; 1987 Dec; 121(6):1931-6. PubMed ID: 3678133
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors.
    Zaccheo T; Giudici D; Lombardi P; di Salle E
    Cancer Chemother Pharmacol; 1989; 23(1):47-50. PubMed ID: 2491793
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Estrogen synthesis in human breast tumor and its inhibition by testololactone and bromoandrostenedione.
    Dao TL
    Cancer Res; 1982 Aug; 42(8 Suppl):3338s-3341s. PubMed ID: 7083197
    [TBL] [Abstract][Full Text] [Related]  

  • 44. RU54115, a tight-binding aromatase inhibitor potentially useful for the treatment of breast cancer.
    Delaisi C; Doucet B; Hartmann C; Tric B; Gourvest JF; Lesuisse D
    J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):773-7. PubMed ID: 1562553
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of 4-hydroxy-4-androstene-3, 17-dione and 10-propargylestr-4-ene-3, 17-dione on the metabolism of androstenedione in human breast carcinoma and breast adipose tissues.
    Perel E; Davis SP; Covey DF; Killinger DW
    Steroids; 1981 Oct; 38(4):397-405. PubMed ID: 7314156
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regulation of ovarian steroid biosynthesis by estrogen during proestrus in the rat.
    Banks PK; Meyer K; Brodie AM
    Endocrinology; 1991 Sep; 129(3):1295-304. PubMed ID: 1874172
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aromatase inhibitors and their potential clinical significance.
    Brodie AM; Wing LY; Goss P; Dowsett M; Coombes RC
    J Steroid Biochem; 1986 Nov; 25(5B):859-65. PubMed ID: 3807367
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of 3-[N-(2-chlorobenzyl)amino]-6-(1H-imidazol-1-yl) pyridazine dihydrochloride on various aromatase enzyme systems and experimental breast cancer.
    Bandoh K; Ishizuka Y; Sato M
    Arzneimittelforschung; 1995 Aug; 45(8):897-900. PubMed ID: 7575757
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modification of the effect of a gonadoliberin analog on 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by hormone replacement.
    Rose DP; Pruitt B
    Cancer Res; 1979 Oct; 39(10):3968-70. PubMed ID: 113083
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of catechol estrogens on rat mammary tumors.
    Abul-Hajj YJ
    Cancer Res; 1979 Dec; 39(12):4882-6. PubMed ID: 115583
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo.
    Schieweck K; Bhatnagar AS; Matter A
    Cancer Res; 1988 Feb; 48(4):834-8. PubMed ID: 2962734
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum estrogens and estrogen responsiveness in 7,12-dimethylbenz[a]anthracene-induced mammary tumors as influenced by dietary fat.
    Ip C; Ip MM
    J Natl Cancer Inst; 1981 Feb; 66(2):291-5. PubMed ID: 6779045
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biochemistry and pharmacology of 7alpha-substituted androstenediones as aromatase inhibitors.
    Brueggemeier RW; O'Reilly JM; Lovely CJ; Ward PJ; Quinn AL; Baker D; Darby MV; Gu XJ; Gilbert NE
    J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):247-54. PubMed ID: 9365197
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High inhibitory activity of a new antiestrogen, RU 16117 (11alpha-methoxy ethinyl estradiol), on the development of dimethylbenz(a)anthracene-induced mammary tumors.
    Kelly PA; Asselin J; Caron MG; Raynaud JP; Labrie F
    Cancer Res; 1977 Jan; 37(1):76-81. PubMed ID: 187338
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prolactin binding to mammary gland, 7,12-dimethylbenz(a)-anthracene-induced mammary tumors, and liver in rats.
    Smith RD; Hilf R; Senior AE
    Cancer Res; 1976 Oct; 36(10):3726-31. PubMed ID: 821605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
    Sonne-Hansen K; Lykkesfeldt AE
    J Steroid Biochem Mol Biol; 2005 Jan; 93(1):25-34. PubMed ID: 15748829
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro transfer rate of 14C from acetate-1-14C into ovarian steroids in the rat ovary during the estrous cycle and effects of LH and FSH.
    Kimura F; Ishida S; Seto K; Kawakami M
    Endokrinologie; 1976 Jun; 67(2):172-83. PubMed ID: 986298
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours.
    Zaccheo T; Giudici D; Ornati G; Panzeri A; di Salle E
    Eur J Cancer; 1991; 27(9):1145-50. PubMed ID: 1835626
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of aromatase inhibitors on the histology of the cycling rat ovary.
    Coney P; Yoshimura Y; Hosoi Y; Bongiovanni A; Wallach E
    Gynecol Obstet Invest; 1987; 23(3):177-83. PubMed ID: 3596353
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of 4-hydroxyandrostenedione and exogenous testosterone on blood concentrations of oestradiol and oviducal embryo transport in the rat.
    Forcelledo ML; Croxatto HB
    J Endocrinol; 1988 Jul; 118(1):93-100. PubMed ID: 3411287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.